|1.||Strony, John: 11 articles (06/2015 - 01/2012)|
|2.||Harrington, Robert A: 11 articles (06/2015 - 01/2012)|
|3.||Van de Werf, Frans: 11 articles (06/2015 - 11/2010)|
|4.||Mahaffey, Kenneth W: 11 articles (06/2015 - 01/2012)|
|5.||Tricoci, Pierluigi: 11 articles (06/2015 - 01/2012)|
|6.||Aylward, Philip E: 10 articles (11/2015 - 01/2012)|
|7.||White, Harvey D: 10 articles (06/2015 - 01/2012)|
|8.||Armstrong, Paul W: 10 articles (06/2015 - 01/2012)|
|9.||Moliterno, David J: 10 articles (05/2015 - 01/2012)|
|10.||Chen, Edmond: 10 articles (05/2015 - 01/2012)|
|1.||Acute Coronary Syndrome
01/01/2015 - "The Thrombin-Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndromes (TRACER) trial investigated safety and efficacy of vorapaxar in patients with an acute coronary syndrome without ST-segment elevation. "
05/15/2015 - "In Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome trial, 12,944 patients with non-ST-segment elevation acute coronary syndromes were randomized to vorapaxar or placebo. "
09/01/2014 - "Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial."
05/05/2014 - "The Thrombin Receptor Antagonist for Clinical Event Reduction (TRACER) trial evaluated vorapaxar compared to placebo in non-ST-elevation (NSTE)-acute coronary syndrome (ACS) patients. "
03/15/2014 - "Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial compared vorapaxar and placebo in 12,944 high-risk patients with non-ST-segment elevation acute coronary syndrome. "
02/01/2008 - "Early data from a clinical trial (TRA-PCI) to evaluate safety and efficacy of a potent new oral thrombin receptor antagonist (TRA) have promisingly indicated that overall TRA treatment reduces adverse event rates without an increase in bleeding risk. "
02/01/1998 - "Seventy-nine patients were entered into a study designed to measure changes in platelet thrombin receptor function during CPB and to correlate them to postoperative bleeding. "
02/01/1998 - "The platelet thrombin receptor and postoperative bleeding."
07/05/2015 - "Platelet transfusion reverses bleeding evoked by triple anti-platelet therapy including vorapaxar, a novel platelet thrombin receptor antagonist."
06/01/2013 - "Expanding antiplatelet therapy from dual to triple therapy including a platelet thrombin receptor antagonist in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial was not associated with a significant reduction in the primary combined endpoint but an increase in bleeding complications. "
07/01/1999 - "An antagonist specific for the thrombin receptor is expected to be a remedy for thrombosis. "
01/01/2013 - "Targeting platelet thrombin receptor signaling to prevent thrombosis."
04/25/2011 - "The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs."
02/01/2003 - "Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates."
10/01/2000 - "Inhibition of arterial thrombosis by a peptide ligand of the thrombin receptor."
|4.||Neoplasm Metastasis (Metastasis)
01/01/2011 - "The emerging role of the thrombin receptor (PAR-1) in melanoma metastasis--a possible therapeutic target."
04/06/2001 - "The first prototype of the protease activated receptor (PAR) family, the thrombin receptor PAR1, plays a central role both in the malignant invasion process of breast carcinoma metastasis and in the physiological process of placental implantation. "
12/01/2001 - "Therefore, the use of antiplatelet agents especially via thrombin receptors may help to prevent TCIPA or metastasis by CCA."
01/01/2014 - "Genetic deletion of the thrombin receptor PAR1 or endothelial thrombin signaling targets alone did not diminish enhanced metastasis in TM(Pro) mice. "
04/29/2010 - "Thorough preclinical investigations have, at least in part, clarified some specifics regarding the involvement of platelet adhesion receptors, such as thrombin receptors or integrins, in the metastasis cascade. "
11/17/2015 - "The Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-Thrombolysis in Myocardial Infarction 50 (TRA 2°P-TIMI 50) was a randomized, double-blind, placebo-controlled trial of vorapaxar in 26 449 patients with previous atherothrombosis. "
03/24/2015 - "Selection of a suitable patient population for new antiplatelet therapy from the large clinical trial database of the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-thrombolysis in myocardial infarction 50 (TRA-2P-TIMI50) trial."
06/01/2013 - "However, in the Thrombin Receptor Antagonist in Secondary Prevention of atherothrombotic ischemic events study in patients with prior myocardial infarction, vorapaxar on top of standard antiplatelet therapy was effective. "
10/01/2000 - "The -5061/D polymorphism of the thrombin receptor (PAR-1) gene is not related to myocardial infarction in the ECTIM study. "
03/01/2008 - "Thrombin receptor and ventricular arrhythmias after acute myocardial infarction."
|1.||Platelet Aggregation Inhibitors (Antiplatelet Drugs)
|4.||von Willebrand Factor
|5.||Purinergic P2Y Receptor Antagonists
|3.||Coronary Artery Bypass (Coronary Artery Bypass Surgery)
|5.||Angioplasty (Angioplasty, Transluminal)